Mankind Pharma Other Announcement
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma has received an improved ESG rating of 64 from CRISIL, categorized as 'Strong'. The rating was assigned independently without company engagement.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) with the exchange. This is a standard periodic disclosure of the company's ownership structure.